A gliclazide is preferred in this patient
B the dose could be increased to 10 mg daily
C the drug is administered in the afternoon
D the drug reduces insulin secretion
E it restores beta-cell activity
As regards glibenclamide therapy?
Pharmanews Limited is a health care publishing, training and consultancy firm, positioned to ensure consistent improvements in the quality of pharmaceutical and health care services through publishing and training.
Pages
© 2025 Pharmanews Limited. All rights reserved.
A
B
B
D
D
Comment:D
A
D